Johnson & Johnson, ASCO 2025: Redefining global cancer care

Mark Wildgust, VP of global medical affairs, oncology, at Johnson & Johnson Innovative Medicine, discusses J&J’s ambition to get in front of cancer.

Liver cancer diagnostic gets FDA breakthrough status, with P...

Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.

On the forefront of healthcare change, turning innovative sc...

Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.

In pursuit of a cure for cancer: An ASCO 2025 discussion wit...

Dr Danny Nguyen, medical oncologist and haematologist at the City of Hope Orange County, spoke with pharmaphorum at ASCO 2025.

The Leukemia & Lymphoma Society at ASCO 2025: Blood cancers ...

Merck at ASCO 2025: Cancer is a constellation of many rare d...